Meetings Events & Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024

The 19th Annual New Orleans Summer Cancer Meeting (NOSCM) 2024 is designed for a diverse group of professionals involved in oncology. The target audience includes:

• Oncologists
• Hematologists
• Radiation oncologists
• Surgical oncologists
• Medical oncologists
• Oncology nurses
• Pharmacists
• Researchers
• Other healthcare professionals involved in cancer care

This meeting aims to provide the latest updates and advancements in cancer treatment, prevention, and survivorship care.

+ Topics:

Acquired Inhibitors in Cancer- State-of-the Art Management.mp4
Addressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship- An Integrative Approach.mp4
ALK- First Line and Mechanism Of Resistance.mp4
Antibody Drug Conjugates for HER2 Negative Breast Cancer- A Revolution in Chemotherapy for Breast Cancer.mp4
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer.mp4
Artificial Intelligence and Modern Medical Practice- Do’s and Don’ts.mp4
Bladder Cancer- Novel Insights and Recent Approvals.mp4
Cancer Care Disparities in Puerto Rico.mp4
Cancer Genetic Risk Factors- What’s New and What You Need to Know..mp4
CAR-T Cell Therapy in Lymphomas- 7-Years Later.mp4
Challenges in Lung Cancer Pathology- Biomarkers.mp4
CLL- Therapeutic Advances in 2024.mp4
Colorectal Cancer- Novel Treatment Paradigms.mp4
Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against).mp4
Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor).mp4
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cance.mp4
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cance_2.mp4
Cost and Access to Novel Therapeutic Agents. Where Are The Obstacles..mp4
ctDNA in Lung Cancer- Current State and Future Perspectives.mp4
De Novo Acute Myeloid Leukemia.mp4
Diabetes Management in the Face of Healthcare Disparities.mp4
EGFR Exon 20 Insertions- Novel Agents.mp4
End of Life Management- Oncologists’ Perspectives.mp4
Equity and Equality for Minorities in Cancer Care.mp4
Immunotherapy for Breast Cancer- Efficacy and Toxicity Considerations.mp4
K-RAS Therapies in NSCLC.mp4
Kidney Cancer- Novel Development in Targeted and Immunotherapy.mp4
Leveraging NCODA Resources to Manage Patients on Oral Oncolytics.mp4
Lifestyle Modifications in Reducing Risk of Recurrence.mp4
los-noscm-2024-flyer.pdf
Lung Cancer With EGFR Exon 19 and L858R Mutations- The Optimal Front Line Therapy.mp4
Malignant Hematology and Use of Bi-specifics in Puerto Rico.mp4
Melanoma- Novel Advances in Immunotherapy.mp4
Metastatic Castration Resistant Prostate Cancer- Sequencing the Treatment.mp4
Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy.mp4
Neuro-Oncology- Novel Advances in Therapy.mp4
Neurology Drug Update.mp4
New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer.mp4
Non Driver NSCLC-The Immunotherapy Strategy.mp4
Novel Advances for Thyroid Carcinoma and Thymoma.mp4
Novel Advances in T-Cell NHL Therapies.mp4
Obesity Management with Incretin Therapies- Considerations for Patients with and without Type 2 Diabetes.mp4
Optimal Surgical Approach in Early Stages NSCLC.mp4
Other Driver Mutations- ROS-1, BRAF, MET and RET.mp4
Pancreas, Hepatic and Cholangiocarcinoma- Advances in 2024.mp4
Pharmacology I- What HemOnc Clinicians Must Know in Immunotherapy.mp4
Prostate Cancer- Early and Locally Advanced Disease.mp4
Role of Pharmacist in Vaccination–Challenges and Opportunities.mp4
Screening in Lung Cancer- Challenges and Obstacles.mp4
Sequencing Therapy in Relapsed-Refractory Myeloma Patients.mp4
Small Cell Lung Cancer- Targeting This Difficult Target.mp4
Soft Tissue and Osteosarcomas- Novel Advances in 2024.mp4
Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR-ABL, FLT3, IDH1-2).mp4
Testicular Cancer- The Old, The New, The Future.mp4
Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies– Focus on PARPi and Other Targeted Ther.mp4
Upper GI Cancer- Esophageal and Gastric-New Developments.mp4
What Is Next After Osimertinib Progression..mp4